ESMO 2014: Phase I/II AURA study of the EGFR inhibitor, AZD9291, in advanced NSCLC

At the European Society for Medical Oncology (ESMO) 2014 Congress, Dr Susan Galbraith (Vice-President Oncology, AstraZeneca) discusses the ongoing phase I/II AURA study of the epidermal growth factor receptor (EGFR) inhibitor, AZD9291, in patients with advanced non-small cell lung cancer (NSCLC) and disease progression while on a previous continuous treatment with an EGFR inhibitor.

Year of Production:
Running Time:
Color/Sound:

2015
03:24
Color/Sound

Comments are closed.